Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Closer Look At China’s 2012 Essential Drug Expansion

This article was originally published in The Pink Sheet Daily

Executive Summary

China is likely to focus on drugs with large consumption patterns for the revised EDL, including anti-hypertensive drugs and oncology drugs.

You may also be interested in...



Hospira Hinges Emerging Market Success On Scale And Differentiation

Hospira Inc.'s new CEO Michael Ball laid out the company's strategic moves to expand in the fast-growing emerging markets during the company's Sept. 7 Investor's Day conference. The CEO said the U.S.-centric company's future growth hinges on expanding its footprint in emerging markets and launching more products including biosimilars in top pharmaceutical markets in Europe and Japan

In China, A Province's Drastic Price Cut Model Is Being Modified To Fit A Nationwide System: A Look At The Anhui Model

SHANGHAI - Since China's healthcare reforms started in 2009, the central government has been encouraging local government to pilot different tender models for essential drugs to reduce public medical expenses. Anhui Province's tender system became a successful example by reducing essential drug prices an average 40-50% last year, and now the central government is implementing a single supplier procurement system, the so-called Anhui model, nationwide

Merck Expands Manufacturing Site In China As Part Of Its Global Restructuring Program

SHANGHAI - Merck announced it would invest $162 million to expand its capacity in China by building a new manufacturing facility, shortly after the company detailed its plans to integrate its R&D, manufacturing and business operations worldwide

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel